Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Clinical trial

NCT04862663

1 development in the corpus

NCT04862663

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 17, 2026 · PHASE 3 TRIAL

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

ClinicalTrials.gov

This is a registry record for an actively recruiting Phase 1b/3 trial with no results posted; it describes study design and planned enrollment only.

PreliminaryRibociclib Palbociclib Locally Advanced (inoperable) Or Metastatic Breast Cancer

Reported

Planned sample size893

Phase 3 primary endpointProgression-free survival

Phase 3 follow-up durationapproximately 47 months

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support